Mandate

Vinge advises Saab in connection with the sale of C3 Technologies

July 14, 2011

Vinge has advised Saab in connection with the sale of the entire issued share capital of C3 Technologies. Saab is the company’s majority shareholder and the company itself is a spin-off from Saab which offers 3D-data to the consumer market based on Saab’s 3D map technology. Saab received a purchase price of approximately SEK 1 billion, which resulted in a profit to Saab of approximately SEK 900 million. The transaction is subject to customary competition law approvals.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, associates Johan Larsson, Johan Mattsson, Adam Weissbach and Malin Buch as well as project assistants Ida Norlin and Mikaela Mars. Partners Per Eric Alvsing and Karin Grauers and associates Claes Henriksson and Daniel Järmén provided IP law advice.  

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026